Tid til tilbagefald (≥50% tab af forbedring) blev evalueret i forsøg ACD2058g og IMP 24011 for patienter, som var klassificeret som respondenter (≥75% forbedring ifølge PASI) efter 12 ugers behandling.
Time to relapse (≥ 50% loss of improvement) was evaluated in Study ACD2058g and IMP 24011 for patients who were classified as responders (≥ 75% improvement on PASI) after 12 weeks of treatment.